Artificial intelligence and machine learning capabilities across the TIA network support multiple stages of therapeutic development. These include computational drug discovery, mRNA and protein design, high-content image analysis, phenotypic screening, predictive toxicity modelling, drug stability assessment and analysis of DNA-encoded library data. Integrated with experimental platforms and supported by high-performance computing and specialised software, these approaches help researchers extract meaningful insights from complex datasets and accelerate the translation of promising therapeutic candidates.

READ MORE HERE